Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

Enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade for recurrence following radical treatment in Japan (Japanese research for patients with non-metastatic castration-resistant prostate cancer-enzalutamide: JCASTRE-zero)—a prospective single-arm interventional study

Abstract Background The effect of enzalutamide in patients with non-metastatic castration-resistant prostate cancer after combined androgen blockade, which represents a patient profile similar to real-world clinical practice in Japan, remains unknown. Therefore, we investigate the efficacy and safet...

Full description

Bibliographic Details
Main Authors: Mikio Sugimoto, Takuma Kato, Yoichiro Tohi, Yosuke Shimizu, Ryuji Matsumoto, Takahiro Inoue, Yutaka Takezawa, Kimihiko Masui, Hiroshi Sasaki, Hiromi Hirama, Shiro Saito, Shin Egawa, Toshiyuki Kamoto, Satoshi Teramukai, Shinsuke Kojima, Takashi Kikuchi, Yoshiyuki Kakehi
Format: Article
Language:English
Published: BMC 2022-09-01
Series:BMC Urology
Subjects:
Combined androgen blockade
Enzalutamide
Non-metastatic castration-resistant prostate cancer
Progression-free survival
Radical treatment
Online Access:https://doi.org/10.1186/s12894-022-01096-3

Internet

https://doi.org/10.1186/s12894-022-01096-3

Similar Items